This review highlights this area of unmet need in CLL, the mechanism of action of BTK protein degraders, a thorough description of the drug development, and the pre-clinic data supporting the early clinical trials in patients with B cell malignancies. The gene discussed is BTK; the disease is B-cell chronic lymphocytic leukemia.